Moderna
Moderna is a biotechnology company focused on messenger RNA therapeutics and vaccines. It develops mRNA-based medicines that instruct cells to produce therapeutic proteins or antibodies in vivo, targeting infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company has built a broad pipeline with multiple development candidates across several modalities and a track record highlighted by a COVID-19 vaccine authorized in the United States. Moderna collaborates with major pharmaceutical and research partners, including AstraZeneca, Merck, Vertex, and Alexion, as well as academic institutions such as Harvard University and Karolinska Institutet. It maintains manufacturing collaborations with Lonza for mRNA production and Catalent for fill-finish, and engages with public sector and philanthropic supporters such as BARDA, DARPA, and the Gates Foundation. As of 2025, the company continued expanding its mRNA development program across infectious disease, oncology, cardiovascular, and rare genetic diseases.
Top Stages
https://app.dealroom.co/companies/***
https://crunchbase.com/organization/***
https://linkedin.com/company/***
7 past transactions
immatics biotechnologies
Post in 2023
immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors.
The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors.
immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.
Generation Bio
Post in 2023
Generation Bio is a genetic medicines company developing durable, redosable treatments for patients with rare and prevalent diseases. Its non-viral platform combines closed-ended DNA, cell-targeted lipid nanoparticles, and scalable manufacturing processes to deliver large and multiple genes across various tissues.
Metagenomi
Series B in 2023
Metagenomi is a genetic medicines company headquartered in Emeryville, California. It leverages metagenomics and machine learning to discover novel genome editing systems from diverse organisms, then convert these natural systems into compact, highly efficient, and specific tools aimed at reducing immune responses. The company maintains a proprietary, metagenomics-derived genome editing toolbox that includes programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), large template RIGS, and CRISPR-associated transposases (CASTs). Its development focus is in vivo gene editing with a wholly owned pipeline, while exploring technology out-licensing for ex vivo cell therapies to pursue curative therapeutics for genetic diseases.
OriCiro Genomics
Acquisition in 2023
OriCiro Genomics is a Japanese biotechnology company founded in 2018, based in Minato-ku. It specializes in developing innovative genome technologies, particularly focusing on cell-free synthesis and amplification of large DNA molecules for synthetic biology applications. The company's core technologies include DNA assembly and circular DNA amplification, which enable the construction of large circular DNA molecules without traditional biological cloning methods. OriCiro Genomics serves life science research and development companies, offering solutions that facilitate advancements in gene therapy, pharmaceuticals, diagnostics, food, and agriculture by leveraging synthetic biology.
Metagenomi
Series B in 2022
Metagenomi is a genetic medicines company headquartered in Emeryville, California. It leverages metagenomics and machine learning to discover novel genome editing systems from diverse organisms, then convert these natural systems into compact, highly efficient, and specific tools aimed at reducing immune responses. The company maintains a proprietary, metagenomics-derived genome editing toolbox that includes programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), large template RIGS, and CRISPR-associated transposases (CASTs). Its development focus is in vivo gene editing with a wholly owned pipeline, while exploring technology out-licensing for ex vivo cell therapies to pursue curative therapeutics for genetic diseases.
Leightal Capital Management
Debt Financing in 2022
Leightal Capital Management is a global hedge fund that invests in a variety of asset classes, including equities, fixed income, and commodities. The fund is managed by a team of experienced professionals with a proven track record of success.
Leightal Capital Management is committed to providing its investors with superior returns over the long term. The fund's investment philosophy is based on the belief that alpha can be generated by identifying and investing in mispriced assets.
The fund's investment team uses a variety of research and analysis techniques to identify mispriced assets. The team also has a strong focus on risk management and capital preservation.
Leightal Capital Management is a good choice for investors who are looking for a long-term investment partner with a proven track record of success.
Onkaido Therapeutics
Venture Round in 2014
Onkaido Therapeutics is focused on developing messenger RNA therapeutics aimed at delivering innovative oncology drugs. The company is advancing pre-clinical drug candidates that target key biological processes such as apoptosis, central regulatory nodes, and immunotherapy. This approach enables healthcare professionals to address a range of oncology-related and infectious diseases that existing treatments may not effectively manage. Through its research and development efforts, Onkaido aims to enhance treatment options for patients facing these challenging medical conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.